289 related articles for article (PubMed ID: 8846536)
1. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients.
Meierhenrich R; Jedicke H; Voigt A; Lange H
Clin Nephrol; 1996 Feb; 45(2):90-7. PubMed ID: 8846536
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
5. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
6. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
7. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure.
Thompson CH; Irish AB; Kemp GJ; Taylor DJ; Radda GK
Clin Nephrol; 1997 Jun; 47(6):372-8. PubMed ID: 9202867
[TBL] [Abstract][Full Text] [Related]
8. Amino acid and alpha-keto acid metabolism depends on oxygen availability in chronic hemodialysis patients.
Riedel E; Nündel M; Wendel G; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S56-60. PubMed ID: 10746807
[TBL] [Abstract][Full Text] [Related]
9. Metformin and exercise: no additive effect on blood lactate levels in health volunteers.
Gudat U; Convent G; Heinemann L
Diabet Med; 1997 Feb; 14(2):138-42. PubMed ID: 9047091
[TBL] [Abstract][Full Text] [Related]
10. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the nutritional status during treatment of anemia using erythropoietin in patients on regular dialysis therapy].
Eiselt J; Veselá E; Racek J
Vnitr Lek; 1994 Jul; 40(7):437-9. PubMed ID: 8073661
[TBL] [Abstract][Full Text] [Related]
13. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
14. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin.
Horina JH; Schwaberger G; Brussee H; Sauseng-Fellegger G; Holzer H; Krejs GJ
Nephrol Dial Transplant; 1993; 8(11):1219-22. PubMed ID: 8302459
[TBL] [Abstract][Full Text] [Related]
15. Blood lactate is reduced following successful treatment of anaemia in haemodialysis patients with recombinant human erythropoietin both at rest and after maximal exertion.
Davenport A; Will EJ; Khanna SK; Davison AM
Am J Nephrol; 1992; 12(5):357-62. PubMed ID: 1489006
[TBL] [Abstract][Full Text] [Related]
16. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
Silberberg J; Racine N; Barre P; Sniderman AD
Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
18. [Use of recombinant erythropoietin on secondary anemia in patients in the terminal phase of renal insufficiency on hemodialysis].
Gasparović V; Puretić Z; Vrhovac B; Gjurasin M; Puljević D
Acta Med Iugosl; 1990; 44(2):129-35. PubMed ID: 2353593
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group.
Laupacis A
Transplant Proc; 1991 Apr; 23(2):1825-6. PubMed ID: 2053167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
